Exicure Inc (XCUR) USD0.0001

Sell:$6.50Buy:$6.80$0.82 (13.76%)

Prices delayed by at least 15 minutes
Sell:$6.50
Buy:$6.80
Change:$0.82 (13.76%)
Deal now
Prices delayed by at least 15 minutes
Sell:$6.50
Buy:$6.80
Change:$0.82 (13.76%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Key people

Andy Yoo
President, Chief Executive Officer, Director
Paul Kang
Co-Chief Executive Officer
Seung Ik Baik
Chief Financial Officer, Company Secretary, Director
Joshua Miller
Chief Accounting Officer
Chang Keun Choi
Director
Ho Jung
Director
Minwoo Kang
Director
Sangwook Song
Director
Dongho Lee
Independent Director
Click to see more

Key facts

  • EPIC
    XCUR
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US30205M3097
  • Market cap
    $37.65m
  • Employees
    8
  • Shares in issue
    6.32m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.